Laboratory Co. of America Holdings (NYSE:LH) Director Kerrii B. Anderson Sells 250 Shares

Laboratory Co. of America Holdings (NYSE:LH) Director Kerrii B. Anderson sold 250 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $200.10, for a total value of $50,025.00. Following the completion of the sale, the director now directly owns 15,722 shares of the company’s stock, valued at $3,145,972.20. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Laboratory Co. of America Stock Performance

Laboratory Co. of America stock traded down $1.07 during trading on Thursday, hitting $200.25. The stock had a trading volume of 593,723 shares, compared to its average volume of 766,163. The company has a quick ratio of 0.76, a current ratio of 0.88 and a debt-to-equity ratio of 0.39. The stock’s 50 day moving average is $210.83 and its two-hundred day moving average is $214.80. Laboratory Co. of America Holdings has a 1 year low of $174.20 and a 1 year high of $234.09. The stock has a market cap of $16.85 billion, a price-to-earnings ratio of 40.29, a price-to-earnings-growth ratio of 1.51 and a beta of 1.02.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $3.68 EPS for the quarter, beating analysts’ consensus estimates of $3.48 by $0.20. Laboratory Co. of America had a return on equity of 14.68% and a net margin of 3.52%. The firm had revenue of $3.18 billion for the quarter, compared to analysts’ expectations of $3.12 billion. During the same quarter in the prior year, the firm earned $3.82 EPS. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. As a group, analysts predict that Laboratory Co. of America Holdings will post 14.87 EPS for the current year.

Laboratory Co. of America Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 12th. Stockholders of record on Tuesday, May 28th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Tuesday, May 28th. This represents a $2.88 annualized dividend and a dividend yield of 1.44%. Laboratory Co. of America’s payout ratio is 57.95%.

Institutional Trading of Laboratory Co. of America

A number of institutional investors have recently modified their holdings of the business. Mendota Financial Group LLC bought a new position in Laboratory Co. of America in the 4th quarter worth about $29,000. Provence Wealth Management Group bought a new position in shares of Laboratory Co. of America in the third quarter valued at approximately $29,000. Tradewinds Capital Management LLC purchased a new position in Laboratory Co. of America during the third quarter valued at approximately $34,000. Exchange Traded Concepts LLC bought a new stake in Laboratory Co. of America during the 3rd quarter worth approximately $37,000. Finally, Bruce G. Allen Investments LLC purchased a new stake in Laboratory Co. of America in the 4th quarter worth approximately $60,000. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LH. Leerink Partnrs restated an “outperform” rating on shares of Laboratory Co. of America in a report on Monday, February 26th. Barclays decreased their price target on Laboratory Co. of America from $234.00 to $213.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. TheStreet lowered Laboratory Co. of America from a “b-” rating to a “c+” rating in a research report on Thursday, February 15th. SVB Leerink began coverage on shares of Laboratory Co. of America in a report on Monday, February 26th. They set an “outperform” rating and a $260.00 price objective on the stock. Finally, Truist Financial lowered their target price on shares of Laboratory Co. of America from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, April 26th. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, Laboratory Co. of America currently has a consensus rating of “Moderate Buy” and a consensus price target of $243.14.

Laboratory Co. of America Company Profile

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).